Joseph Raffaele: Most Patients with “Normal” hsCRP Still Age Faster Than They Realize
Joseph Raffaele, Physician-Scientist in Longevity Medicine, CEO of PhysioAge LLC, posted on LinkedIn:
“There’s an inflammatory paradox most people miss:
Most patients with “normal” hsCRP still age faster than they realize.
Standard reference ranges for high sensitivity C-reactive protein label anything under 3.0 mg/L as “normal.”
Yet research shows cardiovascular risk begins climbing at hsCRP levels above 1.0 mg/L.
That’s a threefold gap between what’s called normal and what actually protects your longevity.
C-reactive protein is produced by the liver in response to acute and chronic inflammation, and elevated levels are linked not just to cardiovascular disease, but to rheumatoid arthritis, inflammatory bowel disease, cancer, and all-cause mortality.
This relationship is especially significant in middle age and beyond, when resilience to inflammation naturally declines.
In my practice, I’ve seen countless patients dismissed as healthy because their hsCRP fell within standard ranges.
Yet they were experiencing:
– Persistent fatigue despite adequate sleep
– Subtle declines in metabolic flexibility
– Stubborn visceral fat accumulation
To me, these are early signals of chronic low-grade inflammation driving accelerated aging.
HsCRP under 1.0 mg/L correlates with significantly lower cardiovascular risk, better metabolic health, and reduced neurodegenerative disease risk.
Here’s my approach:
Start with a high-sensitivity CRP (hsCRP) test to establish your baseline.
If you’re in an acute inflammatory state like an infection, your CRP may spike temporarily above 10 mg/L and should be retested in 4–6 weeks.
Target hsCRP below 1.0 mg/L through precision interventions tailored to the source of inflammation:
𝐋𝐢𝐟𝐞𝐬𝐭𝐲𝐥𝐞 𝐟𝐨𝐮𝐧𝐝𝐚𝐭𝐢𝐨𝐧𝐬: This includes a Mediterranean-style diet emphasizing plant-based meals, regular exercise (both resistance and aerobic training), sleep optimization (poor sleep directly drives IL-6 and TNF-alpha), and smoking cessation if applicable.
𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐰𝐡𝐞𝐧 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥𝐥𝐲 𝐢𝐧𝐝𝐢𝐜𝐚𝐭𝐞𝐝: This can be certain statins and antihypertensives with anti-inflammatory properties, omega-3 optimization (EPA/DHA) targeting an omega-3 index of 8–12%, vitamin E combined with other antioxidants, or emerging modalities like cryotherapy and low-level light therapy (photobiomodulation).
𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬: Inflammatory marker panels to identify LpPLA2 and oxidative stress markers, gut microbiome assessment when dysbiosis is suspected, and continuous glucose monitoring to assess glycemic variability.
Inflammation is not binary.
It exists on a spectrum, and where you sit on that spectrum determines how fast your cells age.
But it’s also modifiable, measurable, and deeply predictive of long-term health outcomes.
Follow me at Dr Joseph Raffaele, for evidence-based longevity insights that help you move from “normal” to optimal.”
Never miss an update from Hemostasis Today.
-
Jun 10, 2026, 18:22Winai Porntipworawech: The $50 Life-Saving Drug Big Pharma Doesn’t Want You to See
-
Jun 10, 2026, 18:09Leonard Valentino: Innovation in Blood Disorders Being Catalyzed by Pathway to Cures
-
Jun 10, 2026, 18:00Smitirupa Mishra: Normal Hemoglobin Does Not Always Mean Normal Genes
-
Jun 10, 2026, 17:58Talat Uppal: Addressing HMB with RACGP’s Dr. Ramya Raman
-
Jun 10, 2026, 17:52Throw Back Thursday to Past Bruises Posted in the Glanzmann’s Research Foundation
-
Jun 10, 2026, 17:52Priya Prasad: In Massive Hemorrhage, Fibrinogen Is Often the First Clotting Factor to Fall
-
Jun 10, 2026, 17:51Mariam Swidan: Some Red Blood Cells Can’t Handle Pressure
-
Jun 10, 2026, 17:49Ankit Mathur: Hosting ISBT Academy Day on Rare Donor Program in India
-
Jun 10, 2026, 17:48Shadi Tabibian: When Patients Bleed but Standard Testing Is Normal